LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials
| Autor: | O'Malley, D.M., Oaknin, A., Monk, B.J., Leary, A., Selle, F., Alexandre, J., Randall, L.M., Rojas, C., Neffa, M., Kryzhanivska, A., Gladieff, L., Berton, D., Meniawy, T., Lugowska, I., Bondarenko, I., Moore, K.N., Ortuzar Feliu, W.I., Ancukiewicz, M., Shapiro, I., Ray-Coquard, I.L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1164-S1165 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|